Steven A. Claas

2.0k total citations
37 papers, 1.3k citations indexed

About

Steven A. Claas is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Genetics. According to data from OpenAlex, Steven A. Claas has authored 37 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cardiology and Cardiovascular Medicine, 15 papers in Molecular Biology and 14 papers in Genetics. Recurrent topics in Steven A. Claas's work include Genetic Associations and Epidemiology (13 papers), Epigenetics and DNA Methylation (9 papers) and Blood Pressure and Hypertension Studies (9 papers). Steven A. Claas is often cited by papers focused on Genetic Associations and Epidemiology (13 papers), Epigenetics and DNA Methylation (9 papers) and Blood Pressure and Hypertension Studies (9 papers). Steven A. Claas collaborates with scholars based in United States, Spain and Canada. Steven A. Claas's co-authors include Donna K. Arnett, Marguerite R. Irvin, Stella Aslibekyan, Devin Absher, Degui Zhi, Stephen P. Glasser, José M. Ordovás, Hemant K. Tiwari, David R. Jacobs and Christopher Armstrong and has published in prestigious journals such as JAMA, Circulation and Nature Genetics.

In The Last Decade

Steven A. Claas

37 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steven A. Claas United States 20 542 282 266 218 169 37 1.3k
M. A. Qadar Pasha India 27 459 0.8× 663 2.4× 260 1.0× 203 0.9× 313 1.9× 69 1.7k
Hong Yuan China 19 339 0.6× 244 0.9× 128 0.5× 90 0.4× 53 0.3× 73 1.4k
Kristine G. Wicklund United States 23 497 0.9× 304 1.1× 263 1.0× 467 2.1× 91 0.5× 33 2.1k
Antti Jula Finland 18 378 0.7× 387 1.4× 345 1.3× 221 1.0× 387 2.3× 31 1.7k
K O Ash United States 22 368 0.7× 210 0.7× 232 0.9× 320 1.5× 167 1.0× 60 1.6k
Shuangyuan Wang China 20 450 0.8× 84 0.3× 164 0.6× 207 0.9× 143 0.8× 67 1.2k
Baqiyyah Conway United States 21 156 0.3× 189 0.7× 162 0.6× 537 2.5× 244 1.4× 41 1.5k
Tuulia Tynkkynen Finland 11 534 1.0× 102 0.4× 91 0.3× 215 1.0× 242 1.4× 19 1.1k
Hao Xue China 23 328 0.6× 122 0.4× 681 2.6× 291 1.3× 190 1.1× 97 1.9k
Niels H. Wacher Mexico 20 324 0.6× 364 1.3× 137 0.5× 358 1.6× 243 1.4× 62 1.4k

Countries citing papers authored by Steven A. Claas

Since Specialization
Citations

This map shows the geographic impact of Steven A. Claas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven A. Claas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven A. Claas more than expected).

Fields of papers citing papers by Steven A. Claas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven A. Claas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven A. Claas. The network helps show where Steven A. Claas may publish in the future.

Co-authorship network of co-authors of Steven A. Claas

This figure shows the co-authorship network connecting the top 25 collaborators of Steven A. Claas. A scholar is included among the top collaborators of Steven A. Claas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven A. Claas. Steven A. Claas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shade, Lincoln M. P., Yuriko Katsumata, Erin L. Abner, et al.. (2024). GWAS of multiple neuropathology endophenotypes identifies new risk loci and provides insights into the genetic risk of dementia. Nature Genetics. 56(11). 2407–2421. 11 indexed citations
2.
Armstrong, Nicole D., Vinodh Srinivasasainagendra, Alana Jones, et al.. (2022). Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study. Genes. 13(7). 1260–1260. 5 indexed citations
3.
Jones, Alana, Marguerite R. Irvin, Steven A. Claas, & Donna K. Arnett. (2021). Lipid Phenotypes and DNA Methylation: a Review of the Literature. Current Atherosclerosis Reports. 23(11). 71–71. 18 indexed citations
4.
Slade, Emily, Marguerite R. Irvin, Kevin Xie, et al.. (2021). Age and sex are associated with the plasma lipidome: findings from the GOLDN study. Lipids in Health and Disease. 20(1). 30–30. 50 indexed citations
5.
Irvin, Marguerite R., Praful Aggarwal, Steven A. Claas, et al.. (2021). Whole-Exome Sequencing and hiPSC Cardiomyocyte Models Identify MYRIP, TRAPPC11, and SLC27A6 of Potential Importance to Left Ventricular Hypertrophy in an African Ancestry Population. Frontiers in Genetics. 12. 588452–588452. 5 indexed citations
6.
Lynch, Amy I., Steven A. Claas, Eric Boerwinkle, et al.. (2016). The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study. Journal of Human Hypertension. 30(9). 549–554. 15 indexed citations
7.
Claas, Steven A. & Donna K. Arnett. (2016). The Role of Healthy Lifestyle in the Primordial Prevention of Cardiovascular Disease. Current Cardiology Reports. 18(6). 56–56. 59 indexed citations
8.
Aslibekyan, Stella, Steven A. Claas, & Donna K. Arnett. (2014). Clinical applications of epigenetics in cardiovascular disease: the long road ahead. Translational research. 165(1). 143–153. 19 indexed citations
9.
N., Anh, Marguerite R. Irvin, Amy I. Lynch, et al.. (2014). The effects of angiotensinogen gene polymorphisms on cardiovascular disease outcomes during antihypertensive treatment in the GenHAT study. Frontiers in Pharmacology. 5. 210–210. 13 indexed citations
10.
Irvin, Marguerite R., Degui Zhi, Stella Aslibekyan, et al.. (2014). Genomics of Post-Prandial Lipidomic Phenotypes in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study. PLoS ONE. 9(6). e99509–e99509. 19 indexed citations
11.
Irvin, Marguerite R., Degui Zhi, Roby Joehanes, et al.. (2014). Epigenome-Wide Association Study of Fasting Blood Lipids in the Genetics of Lipid-Lowering Drugs and Diet Network Study. Circulation. 130(7). 565–572. 151 indexed citations
12.
Aslibekyan, Stella, Robert J. Straka, Marguerite R. Irvin, Steven A. Claas, & Donna K. Arnett. (2013). Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies. Expert Review of Cardiovascular Therapy. 11(3). 355–364. 7 indexed citations
13.
Zhi, Degui, Stella Aslibekyan, Marguerite R. Irvin, et al.. (2013). SNPs located at CpG sites modulate genome-epigenome interaction. Epigenetics. 8(8). 802–806. 120 indexed citations
14.
Arnett, Donna K., Na Li, Weihong Tang, et al.. (2009). Genome-wide association study identifies single-nucleotide polymorphism in KCNB1 associated with left ventricular mass in humans: The HyperGEN Study. BMC Medical Genetics. 10(1). 43–43. 36 indexed citations
15.
Tang, Weihong, Richard B. Devereux, Na Li, et al.. (2009). Identification of a pleiotropic locus on chromosome 7q for a composite left ventricular wall thickness factor and body mass index: the HyperGEN Study. BMC Medical Genetics. 10(1). 40–40. 11 indexed citations
16.
Arnett, Donna K., Richard B. Devereux, D. C. Rao, et al.. (2009). Novel genetic variants contributing to left ventricular hypertrophy: the HyperGEN study. Journal of Hypertension. 27(8). 1585–1593. 29 indexed citations
17.
Lynch, Amy I., Steven A. Claas, & Donna K. Arnett. (2009). A review of the role of atrial natriuretic peptide gene polymorphisms in hypertension and its sequelae. Current Hypertension Reports. 11(1). 35–42. 25 indexed citations
18.
Arnett, Donna K., Steven A. Claas, & Amy I. Lynch. (2009). Has pharmacogenetics brought us closer to ‘personalized medicine’ for initial drug treatment of hypertension?. Current Opinion in Cardiology. 24(4). 333–339. 16 indexed citations
19.
Claas, Steven A. & Stephen P. Glasser. (2005). Long-acting diltiazem HCL for the chronotherapeutic treatment of hypertension and chronic stable angina pectoris. Expert Opinion on Pharmacotherapy. 6(5). 765–776. 19 indexed citations
20.
Arnett, Donna K., Steven A. Claas, & Stephen P. Glasser. (2005). Pharmacogenetics of antihypertensive treatment. Vascular Pharmacology. 44(2). 107–118. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. A. Qadar Pasha Breakdown of academic impact, for papers by Hong Yuan Breakdown of academic impact, for papers by Kristine G. Wicklund Breakdown of academic impact, for papers by Antti Jula Breakdown of academic impact, for papers by K O Ash Breakdown of academic impact, for papers by Shuangyuan Wang Breakdown of academic impact, for papers by Baqiyyah Conway Breakdown of academic impact, for papers by Tuulia Tynkkynen Breakdown of academic impact, for papers by Hao Xue Breakdown of academic impact, for papers by Niels H. Wacher
Rankless by CCL
2026